Trial Profile
A Multicenter Single-arm Study to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia in Chinese Patients With Chronic HBV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 19 Jan 2023 Status changed from recruiting to completed.
- 19 Jul 2020 Planned End Date changed from 31 May 2020 to 31 Jul 2022.
- 19 Jul 2020 Planned primary completion date changed from 31 Oct 2019 to 31 Dec 2021.